Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2020

Pharma News, 2020

Biogen Alzheimer's drug closer to approval with U.S. FDA staff backing, shares jump 40%
Biogen Alzheimer's drug closer to approval with U.S. FDA staff backing, shares jump 40%
(Reuters) - Biogen Inc has shown “exceptionally persuasive” evidence that its experimental Alzheimer’s disease drug is effective, U.
China's Fosun to seek approval for BioNTech's COVID-19 second vaccine, ends trials on first
China's Fosun to seek approval for BioNTech's COVID-19 second vaccine, ends trials on first
SUZHOU, China (Reuters) - BioNTech’s Chinese partner Shanghai Fosun Pharmaceutical Group does not plan to run further clinical trials of the German firm’s coronavirus vaccine candidate tha...
Royalty Pharma tops its record-setting $3.3B deal with CF Foundation, betting $575M more on Vertex's drugs
Royalty Pharma tops its record-setting $3.3B deal with CF Foundation, betting $575M more on Vertex's drugs
Royalty Pharma’s $3.
Bristol Myers Squibb’s psoriasis med hits the mark in phase III
Bristol Myers Squibb’s psoriasis med hits the mark in phase III
Bristol Myers Squibb’s tyrosine kinase 2 (TYK2) inhibitor deucravacitinib outperformed Amgen’s Otezla in a phase III psoriasis study, the pharma company revealed yesterday.
EMA begins evaluation of filgotinib for ulcerative colitis
EMA begins evaluation of filgotinib for ulcerative colitis
Gilead and Galapagos’ application seeking approval for their oral JAK1 inhibitor filgotinib as a treatment for ulcerative colitis has been validated by the European Medicines Agency (EMA).
Resonetics Acquires Medical Business of Hutchinson Technology, Inc.
Resonetics Acquires Medical Business of Hutchinson Technology, Inc.
NASHUA, N.
Novo Nordisk’s Saxenda bags NICE recommendation
Novo Nordisk’s Saxenda bags NICE recommendation
Novo Nordisk’s obesity management treatment Saxenda (liraglutide) has been recommended for use by the UK’s National Institute for Health and Care Excellence (NICE).
Israel begins human trials on COVID-19 vaccine
Israel begins human trials on COVID-19 vaccine
JERUSALEM, Nov.
Pfizer announces €300 million investment in Irish operations
Pfizer announces €300 million investment in Irish operations
Monday, 2nd November 2020 - Today Pfizer is announcing approximately €300 million capital investment in its Irish operations which will support the further development of existing manufacturing site...
Santhera Slashes Workforce in Half After Phase III DMD Failure
Santhera Slashes Workforce in Half After Phase III DMD Failure
Less than a month after the failure of a Phase III Duchenne muscular dystrophy trial (DMD), Switzerland-based Santhera Pharmaceuticals has announced a corporate restructuring that includes the...
UK to pilot new COVID-19 mass testing approach in Liverpool
UK to pilot new COVID-19 mass testing approach in Liverpool
LONDON (Reuters) - Britain will launch a COVID-19 mass testing pilot scheme in the northwest city of Liverpool this week, offering everyone tests whether or not they have symptoms, in an attem...
U.S. approves combination of Pfizer's Upjohn and Mylan
U.S. approves combination of Pfizer's Upjohn and Mylan
WASHINGTON (Reuters) - The U.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand